Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities

Keyphrases

• Risk Factors 100%
• Cardiovascular Toxicity 100%
• Immune Checkpoint Inhibitors 100%
• Immune-related Adverse Events 80%
• Myocarditis 40%
• Tumor 20%
• Disease Management 20%
• High Mortality 20%
• Tyrosine Kinase Inhibitor 20%
• Anticancer Treatment 20%
• Healthcare Management 20%
• High Morbidity 20%
• Female Sex 20%
• Clinical Risk Factors 20%
• Pericarditis 20%
• Radiation Chemotherapy 20%
• Advanced Malignancies 20%
• Vasculitis 20%
• Risk Strategy 20%
• Immune Checkpoint Inhibitor Combination Therapy 20%
• Subclinical Cardiovascular Disease 20%
• Risk Impact 20%

Medicine and Dentistry

• Cardiovascular Toxicity 100%
• Immune Checkpoint Inhibitor 100%
• Cardiovascular System 80%
• Immune-Related Adverse Events 80%
• Myocarditis 40%
• Malignant Neoplasm 20%
• Cancer 20%
• Disease Management 20%
• Cancer Therapy 20%
• Combination Therapy 20%
• Specific Tumor 20%
• Tyrosine-Kinase Inhibitor 20%
• Cardiovascular Disease 20%
• Clinician 20%
• Pericarditis 20%
• Vasculitis 20%